PDCD1 and neoplasm: Predictive biomarkers for individualized immunotherapies are emerging and changing rapidly, with strong differences between entities.44 Here, we used IHC for programmed cell death protein 1 (PD-1)/PD-L1, tumor-infiltrating lymphocytes, microsatellite instability testing, and mutational burden assessment as predictive biomarkers.